NORTH BRUNSWICK, N.J.(BUSINESS WIRE)
Inc., (OTCBB: ADXS). Advaxis, the live, attenuated Listeria
monocytogenes (Lm) immunotherapy company, is advancing the
clinical development of its lead prostate cancer immunotherapeutic
toward clinical trials.
The company is collaborating with Dr. Chandan Guha at the Albert
Einstein College of Medicine and Montefiore Medical Center to
develop ADXS31-142 in human trials. Following the completion of
manufacturing trials, the company intends to conduct a Phase 1 study
with Dr. Guha.
Regarding Advaxis prostate initiative, Dr. John Rothman, Executive VP
of Science and Operations said, Prostate cancer is an excellent target
for immunotherapy. We believe our approach compares favorably with the
recently approved Provenge treatment. Advaxis vaccine is simple and
less expensive, as it is comprised of three (3) vaccinations, which
attack all prostate cancer without the need to be patient specific.?
Advaxis prostate cancer vaccine generates a strong immunologic response
that attacks and kills cells that secrete prostate specific antigen
(PSA), a commonly used clinical indicator of prostate cancer. The
company has published preclinical work demonstrating the ability of
ADXS31-142, its live Listeria vaccine directed against PSA
(Cancer Immunology Immunotherapy. 2008, 57:13011313; Clinical & Vaccine
Immunology, 2009, 16(1):96103).
"The approval of Dendreon Corporation's (NASDAQ: DNDN) Provenge by the
Food and Drug Administration (FDA) is an exciting development in the
study of cancer immunotherapy. Our collaboration with Dr. Guha, coupled
with our recent success in raising funds and some very promising new
preclinical research has led us to commit to moving forward immediately
on a prostate program with our proprietary live Listeria
technology platform,"commented Advaxis Chairman/CEO Thomas A. Moore.
"If human results approach our animal results, we may be able to offer
an immunotherapy that is less expensive, more effective and suitable for
use prior to the induction of chemical castration of prostate cancer
About Dr. Chandan Guha
Dr. Guha is Professor of Radiation Oncology and Professor of Pathology
at the Albert Einstein College of Medicine and Vice-Chairman of
Radio-oncology at the Montefiore Medical Center. He is a member of the
National Cancer Institute's Radio-Therapy Oncology Group (RTOG). Dr.
Guha has received numerous awards and grants in support of his work.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live,
attenuated Listeria monocytogenes (Listeria)
immunotherapeutics that deliver engineered tumor antigens, which
stimulate multiple, simultaneous, immunological mechanisms to fight
cancer. Today, the Company has nine (9) distinct, cancer-fighting
constructs in various stages of development, directly and through
strategic collaborations with such recognized sites of excellence as the City
of Hope, the Roswell
Park Cancer Institute, the National
Cancer Institute, the University
of Pittsburgh and Cancer
Research UK. The Company's technology was developed by Dr. Yvonne
Paterson, professor of microbiology at the University of Pennsylvania
and chairperson of Advaxis scientific advisory board. Please visit the
Company's portals: advaxis.com
Certain statements contained in this press release are
forward-looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are forward
looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements deal with the
Company's current plans, intentions, beliefs and expectations and
statements of future economic performance. Forward-looking
statements involve known and unknown risks and uncertainties that may
cause the Company's actual results in future periods to differ
materially from what is currently anticipated. Factors that could
cause or contribute to such differences include those discussed from
time to time in reports filed by the Company with the Securities and
Exchange Commission. The Company cannot guarantee its future
results, levels of activity, performance or achievements.
Conrad F. Mir, 732-545-1590
Source: Advaxis, Inc.